Cryptis

France-based TxCell and Switzerland’s Ferring International have partnered with Trizell Holding to further enhance the development of TxCell’s Ovasave to treat inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis.

The collaboration, option, development and license agreement between both companies for the product was assigned to Trizell, an affiliate member of the Dr Frederik Paulsen Foundation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

TxCell CEO Damian Marron said: "Products at the forefront of innovation, such as TxCell’s personalised medicine, require expert and dedicated development teams.

"As such, TxCell’s lead product Ovasave for severe refractory Crohn’s disease will benefit enormously from the additional focus and expertise that Trizell will supply."

"The collaboration, option, development and license agreement between both companies for the product was assigned to Trizell, an affiliate member of the Dr Frederik Paulsen Foundation."

In December 2013, the Foundation’s affiliate Ferring signed an exclusive worldwide agreement with TxCell, receiving the option to be the commercialising entity for Ovasave to treat IBD, including Crohn’s disease and ulcerative colitis.

See Also:

The deal is said to be worth €76m ($92.5m), which includes upfront and milestone payments, as well as royalties subject to the achievement of sales milestones, and is unchanged by the Trizell assignment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ferring International executive board president Michel Pettigrew said: "This assignment to the Foundation’s specialist company reinforces our increasing commitment to new products like Ovasave, which offer potential breakthroughs in the treatment for diseases with high unmet medical needs."

Dr Frederik established Trizell to provide specialist management and scientific and development expertise to advanced therapies, including cellular and gene therapies.

TxCell developed ASTrIA, a technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs).

Image: High magnification micrograph of cryptitis in a case of Crohn’s disease. Photo: courtesy of Nephron.